Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis
- 301 Downloads
This study aims to describe the drug use on a Neonatal Intensive Care Unit (NICU) at a University Children’s Hospital in Germany, to investigate the licensing status of the drugs used and to conclude critical areas in neonatal intensive care to support prioritisation of future research.
An 11-month, prospective cohort study was conducted on the NICU at the University Children’s Hospital Erlangen, Germany. All products prescribed during the study period were analysed whether or not the SPC contains information on term and preterm neonates.
A total of 183 patients (102 male) with a mean gestational age of 33.6 weeks (minimum = 24, maximum = 42) were included. The mean length of hospitalisation was 19.4 days (minimum = 2, maximum = 167). On average, patients received 11.1 drugs (minimum = 0, maximum = 46). The majority of prescriptions were accounted for by antibiotics (n = 515), which were received by 90% of all patients, followed by CNS drugs (n = 448) and respiratory drugs (n = 306). Of all the different drugs prescribed (n = 102) only 38% had information regarding their use in patients aged less than 1 month in their SPC. Analgesics and cardiovascular drugs were prescribed frequently, but without having information for use in neonates. Seventy percent of all patients and 100% of very preterm infants received at least one of these drugs.
Treatment strategies on a preterm intensive care unit are complex and little information is available for the drugs used. Analgesics and cardiovascular drugs are of major concern. Efforts will have to be made to conduct well-designed and powered studies in this vulnerable population.
KeywordsDrug utilisation Preterm Neonates Neonatal intensive care unit Unlicensed Off-label
- 5.European Commission (2006) Regulation (EC) No. 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use. European Commission, BrusselsGoogle Scholar
- 7.Senate and House of Representatives of the United States of America (2003) Pediatric Research Equity Act of 2003Google Scholar
- 8.World Health Organisation (2007) Making medicines child size. World Health Organisation, GenevaGoogle Scholar
- 11.WHO Collaborating Centre for Drug Statistics Methodology. Anatomical-Therapeutical-Chemical (ATC) Classification—Index and Guidelines. World Health Organisation, GenevaGoogle Scholar
- 16.Turner MA, Lewis S, Field D (2008) Priorities in neonatal medicines research: a scoping exercise, Abstract, Biannual Meeting ESDPP, RotterdamGoogle Scholar
- 19.Gordon A, Jeffery HE (2005) Antibiotic regimens for suspected late onset sepsis in newborn infants. Cochrane Database Syst Rev CD004501Google Scholar
- 20.Cunha GS, Mezzacappa FF, Ribeiro JD (2003) Maternal and neonatal factors affecting the incidence of bronchopulmonary dysplasia in very low birth weight newborns. J Pediatr (Rio J) 79:550–556Google Scholar
- 22.Stevens TP, Blennow M, Myers EH, Soll R (2007) Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev CD003063Google Scholar
- 23.Soll RF, Morley CJ (2001) Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev CD000510Google Scholar
- 24.Yost CC, Soll RF (2000) Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev CD001456Google Scholar
- 29.European Medicine Agency (2008) Priority list of off-patent medicinal products for paediatric studies. EMEA, LondonGoogle Scholar